

Jozef Bartunek · Marc Vanderheyden  
*Editors*

# Translational Approach to Heart Failure

 Springer

# Translational Approach to Heart Failure



Jozef Bartunek • Marc Vanderheyden  
Editors

# Translational Approach to Heart Failure

 Springer

*Editors*

Jozef Bartunek  
Cardiovascular Centre  
OLV Hospital  
Aalst, Belgium

Marc Vanderheyden  
Cardiovascular Centre  
OLV Hospital  
Aalst, Belgium

ISBN 978-1-4614-7344-2                      ISBN 978-1-4614-7345-9 (eBook)  
DOI 10.1007/978-1-4614-7345-9  
Springer New York Heidelberg Dordrecht London

Library of Congress Control Number: 2013940918

© Springer Science+Business Media New York 2013

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media ([www.springer.com](http://www.springer.com))

# Foreword

The “Dirk Verheyden-foundation” wishes to add the following considerations and reflexions to this scientific foreword.

Young people suffering a heart failure are fighting so hard against this disease. Some win, some lose the fight. It would be a shame if we, healthy people, did not try to continue this battle on another field. That is why we founded the “Dirk Verheyden-foundation” in collaboration with the Cardiovascular Centre of the OLV Hospital in Aalst, Belgium.

With the possibilities we have, we succeeded to raise funds to enable the edition of this book about the experiences and findings of this resolute cardiovascular team.

It gives a sense to the loss of Dirk, our son, brother, friend, and we get a feeling of a resolute continuation of Dirk’s struggle for life.

Our hope and wish is that this book will enable all the cardiac-research teams to get a flow of new findings, results, and experiences so that the progress towards an eventual ban of these cardiac failures can be reached or at least approached.

**SUCCESS.**

The “Dirk Verheyden-foundation.”



# Preface

*In memory of Dirk Verheyden, dedicated teacher and patient.*

The heart failure pandemic is expanding at an alarming pace and has become a leading cause of morbidity and mortality in emerging and developed countries. The hallmark of this pathology is maladaptive ventricular remodeling that precipitates contractile dysfunction, and ultimately leads to the overt syndrome of congestive heart failure. The refined pathophysiological understanding of the heart failure syndrome as well as the surge of new technological advances led to innovative medical and interventional treatment strategies improving the outcome of heart failure patients. However the complex interplay between the clinical presentation and array of existing and emerging interventions requires a coordinated multidisciplinary “heart team” approach involving various specialists in the cardiovascular field including clinicians, interventionalists, surgeons, and cardiac intensivists.

The goal of this book is to provide with an overview of state-of-the-art management of heart failure. It presents a balanced mix of latest updates in the pathophysiology and clinical presentation of heart failure and its associated comorbidities. The topics cover burning clinical questions and challenges faced by the heart team. New medical and interventional therapies for chronic and acute heart failure are addressed by key opinion leaders bridging bench to bedside translation in science and technology towards the practical clinical application and guidance.

The book is divided into four parts. Part I, which aims to bridge pathophysiology of heart failure and its adoption in the clinical management, highlights the modern translational pathophysiology underlying systolic and diastolic heart failure as well as the latest advances in understanding the mechanisms of the cardiorenal syndrome. Ensuing chapter deals with practical guidance on the use of Doppler echocardiography as the most readily imaging tool to diagnose and monitor heart failure. Furthermore, clinical and pragmatic guidance on the methodical approach to a heart failure patient in the era of evidence-based guidelines is presented. The practical, evidence-based management of atrial fibrillation and life-threatening ventricular arrhythmias is further addressed in Part II. This part also provides with an up-to-date review of cardiac resynchronization therapy focusing on the cellular and molecular mechanisms underlying its improvements. In addition, the chapter on



telemonitoring and sensor technologies gives a glimpse on their potential in the ambulatory management and therapeutic tailoring of the heart failure patient. Part III unravels issues related to the role of valvular or revascularization interventions. Mitral valve regurgitation in a heart failure is recognized as a novel “therapeutic target.” Yet, the decision whether and how to intervene remains controversial. The contributors representing stakeholders of the multidisciplinary heart team including clinician, interventionalist, and surgeon will provide with a comprehensive views as well as pragmatic recommendations based on the available evidence and their respective clinical experience. This part will also reflect on the impact of recent clinical trials and controversies surrounding the surgical revascularization and ventricular reconstructive surgery. The final part is dedicated to end-stage heart failure. Cardiologists, intensive care physicians and surgeons share with the reader their opinion on the interventional and surgical management of acute or end-stage heart failure and emerging interventional techniques to reverse the vicious circle of heart failure progression. Readers will become familiar with the clinician-based immunosuppressive approach and management of the post-transplant patient. This part will also review current state-of-the-art in the mechanical support including the use of totally artificial heart as well as promise of novel cell-based interventions.

We want to express our deep gratitude and appreciation to all contributors who have done a commendable job in preparing their outstanding manuscripts. Their thoughtful, detailed, and yet pragmatic approach to each aspect of the heart failure syndrome enabled to reach a comprehensive synthesis of the truly multidisciplinary state-of-the-art management in the twenty-first century.

We wish to thank our many colleagues within the Cardiovascular Centre of the Onze Lieve Vrouw Hospital. Their wisdom and experience paralleled with a search for the continuous advances in patient-tailored management remain inspirational to us. This book is a “harvest” of the Aalst spirit uniquely merging excellence in clinical practice with patient-oriented clinical and translational research. We are also grateful to Mrs. Maggy Kuppens for her excellent and dedicated assistance in preparation of this book. Finally, we both remain indebted to our wives and children. Thanks to their unconditional support and patience, we keep expanding our professional horizons to better serve our patients.

It is our hope that with the current book the reader will be updated with the latest advances in the understanding, management, and treatment of heart failure integrating the multidisciplinary, interventional, and translational approach and yet emphasizing the need for the clinically relevant implementation in daily practice. *It is the patient not the syndrome that we should treat.*

This work has been granted by the Meijer Lavino Cardiac Research Foundation and Dirk Verheyden Fund.

Aalst, Belgium

Jozef Bartunek  
Marc Vanderheyden

# Contents

## Part I Heart Failure: Back to Basics

- 1 Pathophysiology of Heart Failure: Back to Basics.....** 3  
Gilles W. De Keulenaer, Vincent Segers, and Dirk L. Brutsaert
- 2 Heart Failure with Normal Left Ventricular Ejection Fraction:  
Basic Principles and Clinical Diagnostics .....** 25  
Otto A. Smiseth, Espen W. Remme, Anders Opdahl, Svend Aakhus,  
and Helge Skulstad
- 3 Cardiorenal Syndrome Revisited.....** 63  
Matthias Dupont, Wilfried Mullens, and W.H. Wilson Tang
- 4 Echocardiography in the Clinical Evaluation  
of Heart Failure: What Clinicians Need to know  
and Echocardiographers Should Report .....** 91  
Ivan Stankovic and Jens-Uwe Voigt
- 5 Back to Earth: “Common Sense” in the Management  
of Heart Failure .....** 119  
Marc Goethals

## Part II Conduction Abnormalities and Rhythm Disturbances in Heart Failure

- 6 Atrial Fibrillation and Heart Failure: Rate  
Versus Rhythm Control.....** 129  
Mackram F. Eleid, Yong-Mei Cha, and Win-Kuang Shen
- 7 Repetitive ICD Shocks and Incessant VTs in Heart Failure:  
What to Do?.....** 145  
Martin Eisenberger, Tom De Potter, and Peter Geelen

<b>8</b>	<b>Dyssynchronous Heart Failure: From Bench to Bedside</b> .....	169
	Caroline J.M. van Deursen, Lars B. van Middendorp, and Frits W. Prinzen	
<b>9</b>	<b>Telemonitoring and Sensor Technologies in Chronic Heart Failure</b> .....	205
	Matthias Dupont, Wilfried Mullens, and W.H. Wilson Tang	
<b>Part III Functional Mitral Regurgitation in Heart Failure</b>		
<b>10</b>	<b>Functional Mitral Regurgitation: The Surgeons' Perspective</b> .....	241
	Jerry Braun and Robert J.M. Klautz	
<b>11</b>	<b>Percutaneous Approaches to Treat Functional Mitral Regurgitation: Current State of Affairs and Future Perspectives</b> .....	291
	David Messika-Zeitoun	
<b>12</b>	<b>Tailored Approach to Functional Mitral Regurgitation</b> .....	317
	Martin Penicka and Frank Van Praet	
<b>13</b>	<b>Revascularization and Left Ventricular Reconstruction in a Patient with Ischemic Heart Failure: to STICH or not to STICH?</b> .....	335
	Marisa Di Donato	
<b>Part IV When Every Therapy Fails</b>		
<b>14</b>	<b>Cardiac Arrest and Refractory Cardiogenic Shock</b> .....	357
	Koen De Decker	
<b>15</b>	<b>Left Ventricular Assist Devices: From Bridge to Transplant to Destination Therapy</b> .....	385
	Lars H. Lund	
<b>16</b>	<b>Novel Device-Based Strategies in Treatment of Chronic Heart Failure</b> .....	425
	Gabor Toth, Marc Vanderheyden, and Jozef Bartunek	
<b>17</b>	<b>Total Artificial Heart</b> .....	437
	Christof Stamm and Roland Hetzer	
<b>18</b>	<b>Stem Cell Therapy for Ischemic Heart Disease</b> .....	449
	Atta Behfar, Jozef Bartunek, and Andre Terzic	
<b>19</b>	<b>Immunosuppressive Management of the Heart Transplant Recipient</b> .....	467
	Sofie Verstreken	
	<b>Index</b> .....	491

# Contributors

**Svend Aakhus** Department of Cardiology and Institute for Surgical Research, Rikshospitalet, Oslo University Hospital, University of Oslo, Oslo, Norway

**Jozef Bartunek** Cardiovascular Centre, OLV Hospital, Aalst, Belgium

**Atta Behfar** Center for Regenerative Medicine and Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA

**Jerry Braun** Department of Cardiothoracic Surgery, Leids Universitair Medisch Centrum, Leiden, The Netherlands

**Dirk L. Brutsaert** Center of Heart Failure and Cardiac Rehabilitation, AZ Middelheim, University of Antwerp, Antwerp, Belgium

**Yong-Mei Cha** Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA

**Koen De Decker** Department of Anesthesiology and Intensive Care, OLV Hospital, Aalst, Belgium

**Marisa Di Donato** Department Surgical and Medical Critical Care Medicine, University of Florence, Florence, Italy

**Matthias Dupont** Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA

**Caroline J.M. van Deursen** Department of Physiology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands

**Martin Eisenberger** Cardiovascular Centre, OLV Hospital, Aalst, Belgium  
University of South Bohemia, Ceske Budejovice, Czech Republic

**Mackram F. Eleid** Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA

**Peter Geelen** Cardiovascular Centre, OLV Hospital, Aalst, Belgium

**Marc Goethals** Cardiovascular Centre, OLV Hospital, Aalst, Belgium

**Roland Hetzer** Deutsches Herzzentrum Berlin, Klinik Fur Herz-Thorax-und Gefäßchirurgie, Berlin, Germany

**Gilles W. De Keulenaer** Center of Heart Failure and Cardiac Rehabilitation, AZ Middelheim, University of Antwerp, Antwerp, Belgium

**Robert J.M. Klautz** Department of Cardiothoracic Surgery, Leids Universitair Medisch Centrum, Leiden, The Netherlands

**Lars H. Lund** Department of Medicine, Karolinska Institutet, Stockholm, Sweden  
Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden

**David Messika-Zeitoun** Department of Cardiology, AP-HP, Cardiovascular Division, Assistance Publique—Hôpitaux de Paris, Bichat Hospital, Paris, France

**Wilfried Mullens** Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA

**Lars B. van Middendorp** Department of Physiology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands

**Anders Opdahl** Department of Cardiology and Institute for Surgical Research, Rikshospitalet, Oslo University Hospital, University of Oslo, Oslo, Norway

**Tom De Potter** Cardiovascular Centre, OLV Hospital, Aalst, Belgium

**Frits W. Prinzen** Department of Physiology, Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands

**Martin Penicka** Cardiovascular Centre, OLV Hospital, Aalst, Belgium

**Frank Van Praet** Department of Cardiovascular and Thoracic Surgery, OLV Hospital, Aalst, Belgium

**Espen W. Remme** Department of Cardiology and Institute for Surgical Research, Rikshospitalet, Oslo University Hospital, University of Oslo, Oslo, Norway

**Vincent Segers** Center of Heart Failure and Cardiac Rehabilitation, AZ Middelheim, University of Antwerp, Antwerp, Belgium

**Win-Kuang Shen** Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Phoenix, AZ, USA

**Helge Skulstad** Department of Cardiology and Institute for Surgical Research, Rikshospitalet, Oslo University Hospital, University of Oslo, Oslo, Norway

**Otto A. Smiseth** Department of Cardiology and Institute for Surgical Research, Rikshospitalet, University of Oslo, Oslo University Hospital, Oslo, Norway

**Christof Stamm** Deutsches Herzzentrum Berlin, Klinik Fur Herz-Thorax-und Gefäßchirurgie, Berlin, Germany

**Ivan Stankovic** Department of Cardiovascular Diseases, University Hospital Gasthuisberg, Leuven, Belgium

**W.H. Wilson Tang** Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, US

**Andre Terzic** Center for Regenerative Medicine and Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA

**Gabor Toth** Cardiovascular Centre, OLV Hospital, Aalst, Belgium

**Marc Vanderheyden** Cardiovascular Centre, OLV Hospital, Aalst, Belgium

**Sofie Verstreken** Cardiovascular Centre, OLV Hospital, Aalst, Belgium

**Jens-Uwe Voigt** Department of Cardiovascular Diseases, University Hospital Gasthuisberg, Leuven, Belgium

**Part I**  
**Heart Failure: Back to Basics**

# Chapter 1

## Pathophysiology of Heart Failure: Back to Basics

Gilles W. De Keulenaer, Vincent Segers, and Dirk L. Brutsaert

**Abstract** Basic mechanisms of chronic heart failure are reviewed. A central theme that cuts all the way through this review is that chronic heart failure is a problem of failing complexity, rather than a problem of the failure of a single unit (e.g., cell type) or processes (e.g., contractility). A brief paragraph introducing this central concept will precede the main text of this chapter.

Next, a definition of heart failure will be formulated, and the most common etiologies and symptoms of heart failure in clinical cardiology summarized. The progressive nature of chronic heart failure will then be described and its driving forces analyzed. Finally, indices of cardiac performance and heart failure will be summarized and placed into a conceptual frame. The chapter will end by scrutinizing the mechanisms of diastolic dysfunction and by formulating some future trends of heart failure research.


### 1 Introduction

Heart failure is a progressive clinical syndrome for which various definitions and pathophysiologic mechanisms have been proposed. Although cardiac pump dysfunction is an inherent pathophysiological mechanism of heart failure, many extracardiac dysfunctions contribute, especially when heart failure becomes chronic. Accordingly, in this multifactorial syndrome it is difficult to pinpoint the central pathophysiological mechanism. This complicates the introduction in heart failure of therapeutic strategies and of taxonomy, the latter being apparently attractive given the remarkable variability of how this syndrome clinically presents.

---

G.W. De Keulenaer (✉) • V. Segers • D.L. Brutsaert  
Center of Heart Failure and Cardiac Rehabilitation, AZ Middelheim, University of Antwerp,  
Lindendreef 1, 2020 Antwerp, Belgium  
e-mail: gilles.dekeulenaer@ua.ac.be





**Fig. 1.1** The ventricle is a dissipative structure with emerging properties. Analogous to a dissipative structure, the heart grows as an ordered, self-organizing, optimizing pump, or super-system, through fluctuations, interactions and coherence of adjacent subsystems at each higher hierarchic scale, ranging from the subcellular modular networks (available through systems biology research) up to modular networks at the organ level and beyond. At each scale, emerging properties are added

Nevertheless, one may wonder what, if any, could be the central pathophysiological aspect of heart failure? Could it be the maladaptive autoregulatory response upon ventricular dysfunction, involving hormones and paracrine factors, and the consecutive process of ventricular remodeling? Or should one perhaps look at lower structural/functional scales, e.g., impairment of cardiac muscle mechanical performance due either to failing excitation-contraction-relaxation coupling, or to disturbed cross-bridge cycling? Alternatively, could it be the repercussion of left ventricular dysfunction on the periphery including atria, the pulmonary circulation, the right ventricle, the kidneys, and skeletal muscles? Which of these phenomena is the most crucial, pernicious, irreversible?

These questions have no single answer as heart failure is the failure of a complex system; failure of a complex system cannot be reduced to the failure of a single process. The ventricle itself is a complex system, which means that its properties follow the scientific rules of complexity. These rules are characterized by mathematic phenomena like nonlinearity and self-organization, which provide the ventricle with all the properties of a “dissipative structure” [1–3]. This means that the ventricle behaves as a dynamic and self-organizing structure with emerging properties at each higher hierarchical scale of performance (Fig. 1.1).

From this perspective, *ventricular dysfunction and the heart failure syndrome are problems of failing complexity rather than the sum of failures of one or more components of the cardiovascular system.*


Application of scientific principles of “complex system behavior and failure” to the syndrome of chronic heart failure is unfortunately only in its infancy [4]. Heart failure is often described and subdivided from within a narrow oversimplified perspective, i.e., a single gene or gene product, a single cell type (e.g., the cardiomyocyte), a single parameter (e.g., left ventricular ejection fraction (LVEF)), a single functional aspect (e.g., contractility, filling), a single organ (e.g., the heart). In the next chapter, we discuss the pathophysiology of chronic heart failure avoiding the bias to such a narrow perspective. We also address some future perspectives and the need of introducing complex systems biology in the analysis of chronic heart failure.

## 2 Main Text

### 2.1 Definition and Pathophysiology of Heart Failure

Heart failure is a complex clinical syndrome characterized by fatigue and tissue congestion related to cardiac pump dysfunction. Cardiac pump dysfunction in heart failure may either impart impaired ventricular filling (predominantly diastolic pump dysfunction/failure) or impaired ventricular output (predominantly systolic pump dysfunction/failure), but it almost always consists of a combination of both impairments. There is currently insufficient evidence to subdivide heart failure in pathophysiological entities based on whether a diastolic or systolic impairment dominates, although this issue is currently still under debate [1, 5]. Subdivision of heart failure in distinct entities based on systolic/diastolic function (“systolic” and “diastolic” heart failure) is complicated by the fact that systolic and diastolic dysfunction nearly always coexist, that ventricular contraction and relaxation are physiologically coupled, and that there is no single criterion to precisely define a systolic or diastolic heart failure sub-entity. Most if not all heart failure indices show mere quantitative variations along the wide spectrum between predominantly concentric (“diastolic” heart failure) and eccentric (“systolic” heart failure) hypertrophy, and often follow a continuous linear relation when plotted against the patient’s corresponding LVEF (Fig. 1.2) [6–9]. Cut-off values of these indices to introduce distinct heart failure sub-entities have been arbitrary. Hence, the connotations “diastolic” and “systolic” heart failure, or heart failure with a preserved (HFPEF) or reduced ejection fraction (HFREF), may have practical advantages in daily clinical medicine, but lack a conceptual basis.

*Accordingly, heart failure emerges as a heterogeneous, but undividable spectrum of numerous overlapping phenotypes.* Hence, at least from a pathophysiological



**Fig. 1.2** Schematic presentation of the gradual distribution of heart failure parameters of the whole spectrum of disease. Opposite to a binary view on heart failure, most parameters of heart failure do not cluster in two groups (“low” and “high”) when plotted against left ventricular ejection fraction (LVEF). Instead, they follow an uninterrupted linear relation over the whole spectrum of the syndrome (from low to high LVEF). *S-LAX* systolic long axis displacement of the mitral annulus, *LV EDV* left ventricular end diastolic volume, *LogNTproBNP* logarithm of the serum concentration of N-terminal brain natriuretic peptide. See text for references

perspective, it is artificial to subdivide heart failure in distinct disease entities. Heart failure’s heterogeneity (e.g., forward and backward failure, systolic and diastolic failure, right and left ventricular failure) may, however, be accompanied by wide variations in prognosis and clinical responses to therapeutic (pharmacological and non-pharmacological) interventions. Thus, in daily clinical practice, medical management of heart failure should be individualized based on the specific phenotypic characteristics of the patient and the stage of the syndrome.

### Key Points

- From a pathophysiological perspective chronic heart failure emerges as a heterogeneous, but indivisible spectrum of overlapping phenotypes.
- Surviving heart failure phenotypes in 2 or more so-called “disease entities” such as “HFNEF” and “HFPEF,” “systolic” and “diastolic” heart failure, or “isch-

**Table 1.1** Causes of heart failure

---

1. Cardiomyopathies
(a) Ischemic heart disease (infarction, stunning, hibernation)
(b) Genetic cardiomyopathy (dilated and hypertrophic)
(c) Infectious/inflammatory cardiomyopathy
(d) Metabolic cardiomyopathy (e.g., obesity, diabetes)
(e) Toxic cardiomyopathy (e.g., cancer drugs)
(f) Infiltrative cardiomyopathy (e.g., amyloidosis)
2. Myocardial overload
(a) Pressure overload (e.g., hypertension, aortic stenosis)
(b) Volume overload (e.g., mitral/aortic regurgitation)
3. Pericardial diseases
(a) Constrictive pericarditis
(b) Pericardial effusions (tamponade)
4. Electrical abnormalities
(a) Dyssynchrony
(b) Bradycardias
(c) Tachycardias

---

emic” and “non-ischemic” cardiomyopathy may have some clinical advantages in current clinical medicine, but this should be done carefully, and should never dominate pathophysiological research.

## 2.2 Etiology of Heart Failure

Heart failure may be the end stage of all forms of cardiovascular disease, and of many different risk factors, contributing to the heterogeneity of the syndrome. The causes of cardiac dysfunction leading to heart failure may be subdivided into whether they directly affect myocardial or ventricular function (e.g., ischemia, toxicity, gene dysfunction, metabolic dysfunction) or place an abnormal load on the myocardium (volume of pressure overload), resulting in impairment of ventricular function (Table 1.1). In most instances, the mechanisms of progression from cardiac insult to cardiac dysfunction and finally to the full-blown syndrome of heart failure are not well understood. *These mechanisms clearly surpass the structural and functional changes of the left ventricle and also involve a complex interaction of neuroendocrine, vascular, and other noncardiac processes.* Importantly, most currently available therapies of chronic heart failure target neuroendocrine and vascular processes, rather than the structural and functional changes of the ventricle per se. The complexity of pathophysiological processes in chronic heart failure seems common to most if not all causes of heart failure and contributes to the progressive character of the syndrome, to advancing symptoms and to premature death.

**Key Point**

- A list of etiological factors of heart failure in clinical cardiology is provided.

### ***2.3 Symptoms of Heart Failure and Causes of Death***

The major signs and symptoms of chronic heart failure are fatigue, exercise intolerance, breathlessness, and tissue edema. They may remain absent for a long period during disease development despite dysfunction of the heart first as a muscular and even as a hemodynamic pump. Once they develop, they may be present in different degrees and combinations. Consistent with the complexity of the heart failure syndrome, the origin of these signs and symptoms cannot linearly be explained by a single mechanism, although they somehow originate from dysfunction of the heart. Symptoms and signs of heart failure are the result of a combination of both cardiac and extra-cardiac dysfunctions of chronic heart failure.

*Fatigue*, particularly during exercise, is a common presenting symptom of chronic heart failure. It is often difficult to distinguish from breathlessness. The mechanism of fatigue is complex and poorly understood [10]; it clearly surpasses failure of the left ventricle as a hemodynamic pump (as it correlates poorly with LVEF). Impaired cardiac chronotropic reserve [11], muscle blood flow, deficient endothelial function [12], and disordered skeletal muscle structure and function have been involved [13].

*Breathlessness* is equally complex and poorly understood. It also surpasses mechanisms related to dysfunction of the ventricle as a muscular and hemodynamic pump; some studies showed correlations with left ventricular diastolic function, whereas other didn't [14]. Other heart failure-related, but extra-cardiac mechanisms, likely play a role including an exaggerated ventilatory response to exercise, resulting in an abnormally steep VE/VCO<sub>2</sub> slope [15].


*Tissue edema* is related to the retention of salt and water in the kidneys, which on its turn is related to the activation of the renin-angiotensin-aldosterone system (RAAS), rather than to intrinsic dysfunction of the kidneys. To what extent RAAS activation is related to reduction in renal blood flow is, however, unclear.

**Key Point**

- Symptoms and signs of heart failure are not explained by dysfunction of a single process, but are the result of a complex interplay of mechanisms, both cardiac and extra-cardiac.

### ***2.4 Progression of Chronic Heart Failure: Pathophysiology and Therapeutic Targets***

The progressive nature of chronic heart failure has been the subject of intense research. Usually, its progression is explained by the vicious circle paradigm in which



**Fig. 1.3** Heart failure is a progressive disease. Each of the figures highlights a different aspect of the progression. In the vicious circle paradigm of heart failure (*left*), the pernicious, progressive, and irreversible character is emphasized as propelled by endothelial dysfunction, (mal) adaptive activation of neurohormones and cytokines. In the *middle* figure, the progressive nature of heart failure is equally emphasized, but focus is on the consecutive stages of failing cardiac performance, i.e., failure of the heart first as a muscular suction pump, then as a hemodynamic compression pump and finally of the whole cardiovascular system, with drop in stroke volume (SV), cardiac index (CI), and eventually of arterial blood pressure (Part). The spectrum paradigm of heart failure (*right*) visualizes how during heart failure progression each patient follows a unique disease trajectory. The trajectories depend on the relative contribution of the patient’s traits and comorbidities (coined disease modifiers), are thus patient-specific, and hence create a spectrum of phenotypes throughout the entire population of heart failure patients

driving forces including hemodynamic disturbances, neurohormones, cytokines, and endothelial activation/dysfunction lead to successive failure of the heart as a muscular pump and hemodynamic pump, finally of the whole circulatory system. Within these progression, each patient follows its unique disease trajectory, in which LVEF remains preserved or gradually drops while symptoms develop (Fig. 1.3).

*Hemodynamic disturbances.* Ventricular pressure and volume overload (either directly related to the cause of heart failure, or indirectly induced by renal sodium/water retention and neurohormone-mediated vasoconstriction of arterioles) undoubtedly contribute to the progress of ventricular remodeling and heart failure, at least partly through effects of Laplace’s law on ventricular wall stress. Therapeutic interventions aimed at reducing hemodynamic disturbances in heart failure (positive inotropes, diuretics, vasodilators) may reduce symptoms of heart failure. Their effects on mortality due to heart failure have, however, been disappointing [16–18].


*Neurohormonal activation.* Increased activity of the RAAS and of the sympathetic nervous system as well as activation of a wide variety of circulating and tissue hormonal systems are characteristic of the heart failure syndrome. These systems contribute importantly to the progression of ventricular remodeling and heart failure.

Therapeutic interventions aimed at reducing the activity of these systems (angiotensin converting enzyme inhibitors, angiotensin type I receptor antagonists, beta-1 receptor antagonists, and aldosterone receptor antagonists) have systematically reduced symptoms and mortality of heart failure, sometimes despite (temporarily) exacerbating the concomitant hemodynamic disturbances [19–22].

*Cytokine activation.* Cytokines are cell products released in response to tissue injury and inflammation. Increased serum concentrations of several cytokines have been shown in heart failure, including various interleukins (IL-6, IL-33, etc.) and tumor necrosis factor alpha (TNF $\alpha$ ). Cytokines have been postulated to contribute to ventricular remodeling, but also to skeletal muscle wasting and cachexia. Therapeutic interventions directly targeting the effects of cytokines in heart failure have, however, not resulted in improved outcomes [23].

*Endothelial activation/dysfunction.* The endothelium in heart and vessels releases a number of local factors, both in rest and in response to a variety of stimuli, that exert effects on contractility, relaxation, passive stiffness, electrophysiology, survival and growth of cardiac and vascular cells [24]. In heart failure, the release of some of these factors is impaired, like nitric oxide, whereas the release of others is increased, like endothelin-1. Therapeutic interventions directly restoring the activity of one or more of these endothelial factors in heart failure have not yet resulted in a long-term survival benefit. There are promising preliminary data, however, with a recently discovered endothelial factor, neuregulin-1, which exerts cardioprotective and cardioregenerative effects [25]. Long-term studies still have to be performed.

*Left ventricular remodeling.* Although surpassing cardiac abnormalities, one of the key features of the heart failure syndrome is the pernicious process of cardiac remodeling (Fig. 1.4). This process is characterized by a progressive change in shape, volume, and muscle mass of the left ventricle, often accompanied by changes in shape and volume of the left atrium. Although ventricular remodeling is often assigned to be either eccentric (when left ventricular end diastolic volume increases) or concentric (when left ventricular walls thicken), eccentric and concentric remodeling often coexist, indicating that heart failure cannot be dichotomized into two distinct disease entities based on the ventricle's type of remodeling and its pathological architecture. *Ventricular dilatation* during cardiac remodeling has a potential hemodynamic advantage by preserving stroke volume without increasing contractility, but the disadvantage of this process is that it also augments ventricular wall stress (as defined by Laplace's law). Increased wall stress increases myocardial oxygen consumption and reprograms myocardial gene expression. *Ventricular wall thickening* has the advantage of normalizing wall stress when overcoming pressure overload, but it has the disadvantage of disturbing the relation between myocytes and microcapillaries [26]. Hence, ideally for a long term survival of chronic heart failure, a balanced spectrum of remodeling may be essential.




**Fig. 1.4** Left ventricular remodeling results in a spectrum of cardiac phenotypes. Left ventricular remodeling is the result of an interplay of many complex processes in cardiac cells (endothelial cells, cardiomyocytes, fibroblasts, ...). These processes are dependent on many mediators (reactive oxygen species, hyperglycemia, neurohormones, mechanical strain, sex hormones, etc.) whose contribution is dependent on the patient's phenotype and risk factors (e.g., gender, diabetes, coronary failure, and body mass index). Some mediators promote concentric remodeling (e.g., estrogens, leptin) whereas other promote eccentric remodeling (ischemia; inflammation, etc.). The relative contribution of each of the processes is unique for each patient, leading to a spectrum of cardiac phenotypes when a large group of patients is considered

Ventricular remodeling is the result of multiple interacting complex signaling processes, the contribution of which is linked to the patient's biological traits and comorbidities. Some of these signaling processes are linked to coronary failure, myocardial infection, or type 1 diabetes mellitus; these promote predominantly eccentric remodeling. Others, such as type 2 diabetes mellitus, obesity, hypertension, and female gender, instead tend to promote concentric remodeling [27–32]. The complex signaling processes triggered by each of the disease modifiers separately (or of their mediators, such as leptin, ischemia, hyperinsulinemia, and estrogen) are under intense investigation. In vivo, these complex signaling processes merge in qualitative and quantitative combinations, specific for each patient and leading to a spectrum of overlapping profiles of ventricular remodeling.

The cellular and subcellular processes during cardiac remodeling are extremely complex. Changes occur at the level of individual cardiomyocytes, fibroblasts, endothelial cells, purkinje fibers and cardiac stem cells, and also the communication






**Fig. 1.5** Autoregulatory control systems of the heart. Cardiac endothelium-cardiomyocyte cross-talk is part of the autoregulatory control systems of the heart, together with the neurohormonal system and the Starling mechanism. Accordingly, cardiac endothelium dysfunction may lead to cardiomyopathy and heart failure. This relative simple concept has recently been underscored by the unexpected cardiac side effect induced by trastuzumab, an inhibitory antibody of the receptor tyrosine kinase ErbB2, which mediates cellular effects of the cardiac endothelium-derived factor neuregulin-1. Inhibition of the cardiac actions of neuregulin-1 with trastuzumab leads to left ventricular dysfunction and heart failure, which is reversible upon interrupting treatment with trastuzumab

between these cells, one of the crucial autoregulatory mechanisms of ventricular function is affected (Fig. 1.5) [33]. *Cardiomyocytes* undergo growth and apoptosis and receptor-signaling pathways of numerous hormonal and paracrine growth and survival factors (such as angiotensin II, endothelin-1, interleukin-6, IGF-1, and neuregulin-1) in the myocytes are activated. Essential myocyte functions like excitation-contraction-relaxation coupling [34] and adrenergic responsiveness [35] are disturbed. *Fibroblast* collagen synthesis is activated, but the release of enzymes for collagen degradation is also increased. Angiogenesis, controlled by *endothelial cells*, becomes impaired in the failing heart, contributing to maladaptive hypertrophy and transition to failure [26].

*Cardiomyocyte renewal.* The classical view on myocardial turnover and regeneration has been that cardiomyocytes are terminally differentiated cells and that no new cardiomyocytes are formed during adult life. This classical view has been challenged by recent data showing that new myocytes are formed during adulthood, both during normal aging and after myocardial injury. However, renewal of cardiomyocytes either by stem cells or cardiomyocyte division seems to be insufficient to repair myocardium and prevent heart failure after myocardial infarction. Stem cell biology has only recently been incorporated into the study of heart failure, and evidence of stem cell dysfunction as a part of heart failure pathophysiology is mounting. Development and progression of heart failure could be due in part to failure of cardiac stem cells; strategies that are focused on stem cell dysfunction might become available as a therapy in the future [36].

### Key Points

- Chronic heart failure has a progressive nature, the mechanisms of which are still under investigation. Its driving forces provide therapeutic targets.



**Fig. 1.6** Conceptual approaches to cardiac performance. The ventricle can be considered as part of a hydraulic input–output system with the ventricle as a *black box* (organism panel), as a hemodynamic compression pump with the cardiomyocytes as a *black box* (organ panel), as a muscular suction pump with the non-cardiomyocytes as a *black box* (tissue panel), as a pluricellular tissue pump with genes and proteins as *black box* (cell panel) or as the product of the individual’s genome, epigenome, and proteome (gene panel). Within each panel-specific approach to cardiac performance, different phenotypes of heart failure can be proposed (forward and backward failure, systolic and diastolic heart failure, contractility and suction failure, multi-biomarker-based forms of heart failure, and perhaps in the future genomic-proteomic-based types of heart failure). While recording variables of cardiac function, they should be placed in their correct conceptual frame. *LV EDV* left ventricular end diastolic volume; *LA* left atrium, *BNP* brain natriuretic peptide, *TGF* tissue growth factor, *CRP* C-reactive protein, *MMP* matrix metallo-proteinase, *Tn-I* troponin-I, *SNP* single nucleotide polymorphism, *GWAS* genome wide association study

- Progression of heart failure is accompanied by structural and functional changes of the heart (“ventricular remodeling”), which result from multiple and interacting signaling processes.

### 2.5 How to Measure Cardiac Performance in Heart Failure and Characterize the Syndrome?

Diagnosis and follow-up of heart failure requires assessment of cardiac performance. Cardiac performance can be assessed at many different levels of the heart’s functional complexity (Fig. 1.6), providing many possible performance indices and heart failure variables. Variables of heart failure may fit in a general circulatory context, like blood pressure and peripheral/pulmonary vascular resistance, which often receive large attention in the clinical setting of acute cardiac failure and

circulatory shock. They do not reliably reflect the function of the pump, however, since they can be normal in advanced stages of pump dysfunction.

Parameters of pump function may reflect the function of the left ventricle (LV) as a *hemodynamic pump* (e.g., LVEF and LV end systolic elastance) or they may reflect the function of the LV as a *muscular pump* (e.g., myocardial segment strain, (un)twisting velocities). This differentiation is important since in some stages/phenotypes of heart failure hemodynamic pump parameters are still preserved, giving the false impression that LV function is normal, despite severe dysfunction of the muscular properties of the ventricle (e.g., in the setting of HFPEF, or in the setting of “low gradient aortic valve stenosis and a normal LVEF”). Next, serum biomarkers such as serum natriuretic peptides, metallo-proteinases, endothelin-1, and neuregulin-1 are indices of heart failure reflecting (secretory) processes of myocardial cells. Biomarkers usually are very sensitive parameters of heart failure, increased in early stages of LV dysfunction, even when LVEF is still normal. Finally, expression levels of mRNA's and micro-RNA's, to be quantified in isolated myocardial tissue or in serum, reflect DNA activities of cardiac cells and may be used in the diagnosis or staging of heart failure, although this is still experimental to date.

Recording these variables of cardiac performance and heart failure gives a reliable picture of the severity and the stage of the disease in an individual patient. For example, measuring increased levels of serum natriuretic peptides, reduced left ventricular untwisting velocities but a normal LVEF indicates that heart failure has progressed up to the stage of dysfunction of the muscular pump, but that performance of the heart at a higher hierarchic level is still intact (often due to activation of compensatory processes which optimize the function of the hemodynamic pump, despite dysfunction of the heart at the level of the cardiac muscle and lower levels of complexity).

*Interestingly, within each hierarchic level of cardiac dysfunction, different “clinical phenotypes” of the heart failure syndrome can be identified, which refers to with the above mentioned clinical heterogeneity of the syndrome.* For example, when heart failure has progressed up to the most severe stage, i.e., failure of the heart as a hydrodynamic input–output system, it may clinically present as *forward or backward heart failure*. Similarly, when heart failure has progressed up to the level of the hemodynamic pump clinical phenotypes of predominant *systolic or diastolic heart failure* may be differentiated. Currently, there are attempts to define heart failure subtypes based on a *multi-biomarker panel*. None of these “phenotypes” of heart failure should be viewed as a distinct disease entity. They are mere variant clinical presentations in a spectrum of heterogeneous phenotypes, to which therapeutic interventions should be tailored.

### **Key Point**

- All indices of cardiac performance and failure fall within a specific conceptual approach to cardiac performance.

## 2.6 Diastolic Dysfunction

Most if not all forms of heart failure, independently of LVEF, display a certain degree of diastolic dysfunction. In fact, in many clinical condition, i.p. ischemic heart disease and hypertrophic cardiomyopathy, relaxation and filling abnormalities occur long before contraction and ejection abnormalities.


Although often subject of misinterpretation, at least from the perspective of the heart as muscular pump, “true” diastole of the ventricle only starts after early rapid ventricular filling, and hence encompasses diastasis and the atrial contraction phase. Pressure fall during isovolumic relaxation in the pump (that fully completes at end systolic volumes) and the increase in pump volume during early rapid filling are strictu sensu still part of the contraction-relaxation cycle of the ventricular muscular “systole.” Diastolic failure then refers to a disease process that shifts the end portion of the pressure–volume diagram inappropriately upward so that LV filling pressures are increased disproportionately to the magnitude of LV dilatation (Fig. 1.7). The causes of such a shift can be subdivided into (Table 1.2):

1. Decrease in ventricular diastolic compliance (i.e., true diastolic failure)
2. Slow ventricular systolic relaxation (i.e., diastolic failure secondary to impaired systolic function of the muscular pump)
3. Inappropriate tachycardia (e.g., transient atrial fibrillation, supraventricular tachy-arrhythmias) (i.e., diastolic failure secondary to inappropriate abbreviation of diastolic duration)
4. A combination of a, b, and c, as is usually the case.

Causes of impaired relaxation and/or compliance can be divided into (1) Factors intrinsic to the cardiomyocyte, (2) factors within the extracellular matrix (ECM) that surrounds the cardiomyocytes, and (3) factors that activate the production of neurohormones and paracrine substances.

*Cardiomyocyte.* Elements and processes intrinsic to the cardiomyocyte contributing to diastolic (dys)function have been summarized in Table 1.2. In general they relate to processes responsible for calcium removal from the myocyte cytosol (calcium homeostasis), to processes involved in cross-bridge detachment and to cytoskeletal functional elements. Changes in any of the processes and elements can lead to abnormalities in both active relaxation and passive stiffness.

1. *Calcium homeostasis.* Abnormal activity of SERCA2 has been implicated in the impaired relaxation in heart failure. SERCA2 activity declines in LV hypertrophy and heart failure by reduced gene and protein expression and by reduced phosphorylation of its inhibitory modulatory protein phospholamban (PLB) [37–40]. Conversely, experimental gene transfer with SERCA2a or a negative PLB mutant improves relaxation [41, 42]. It is as yet unclear at which stages of chronic heart failure SERCA2 activity becomes affected [43]. By all means, impaired SERCA2 activity is certainly not specific for HFPEF, as it will become more pronounced when global pump performance is reduced [37].



**Fig. 1.7** Subdivision of the cardiac cycle from the perspective of the heart as a muscular pump. Taking into account that the heart is a muscle, “true” diastole of the ventricle only starts after early rapid ventricular filling, and hence encompasses diastasis and the atrial contraction phase. At normal rest heart rates, diastole usually lasts for approximately 50 % of the total time duration of the cardiac cycle. Pressure fall during isovolumic relaxation in the pump (that fully completes at end systolic volumes) and the increase in pump volume during early rapid filling are strictu sensu still part of the contraction-relaxation cycle of the ventricular muscular “systole.” Diastolic failure then refers to a disease process that shifts the end portion of the pressure–volume diagram inappropriately upward so that LV filling pressures are increased dysproportionally to the magnitude of LV dilatation

**Table 1.2** Mechanisms of diastolic dysfunction

<b>Mechanisms of diastolic dysfunction</b>		
<b>Inappropriate tachycardia</b>	<b>Impaired Load Dependence of Relaxation</b>	<b>Ventriculo-Arterial stiffening</b>
Intermittent atrial fibrillation; atrial tachyarrhythmias	<ul style="list-style-type: none"> <li>- <b>Excessive Load</b> <ul style="list-style-type: none"> <li>• pressure-volume overload</li> </ul> </li> <li>- <b>Impaired Inactivation</b> <ul style="list-style-type: none"> <li>• calcium homeostasis                             <ul style="list-style-type: none"> <li>✓ calcium overload</li> <li>✓ calcium transport (sarcolemma, SR)</li> <li>✓ modifying proteins (phospholamban, calmodulin)</li> </ul> </li> <li>• myofilaments                             <ul style="list-style-type: none"> <li>✓ Tn-C calcium binding</li> <li>✓ Tn-I phosphorylation</li> <li>✓ myofilament calcium sensitivity</li> <li>✓ Myosin Binding Protein C</li> </ul> </li> <li>• energetics                             <ul style="list-style-type: none"> <li>✓ ADP/ATP ratio</li> <li>✓ ADP and Pi concentration</li> </ul> </li> </ul> </li> <li>- <b>Excessive Non-uniformity of load or inactivation in space or time</b></li> <li>- <b>Abnormal activity of RAAS, OS, ANP/BNP, cardiac endothelial system</b></li> </ul>	<p><b>INTRACARDIAC: Hypertrophy</b></p> <ul style="list-style-type: none"> <li>- <b>Cytoskeletal abnormalities</b> <ul style="list-style-type: none"> <li>• microtubules (tubulin)</li> <li>• intermediates filaments (desmin)</li> <li>• <b>Increased N2B/N2BA titin</b></li> <li>• Nebuline</li> </ul> </li> <li>- <b>Extracellular matrix</b> <ul style="list-style-type: none"> <li>• fibrillar collagen</li> <li>• basement membrane proteins</li> <li>• proteoglycans</li> <li>• MMP/TMP</li> </ul> </li> <li>- <b>Abnormal activity of cardiac endothelial system (especially NO)</b></li> </ul> <p><b>EXTRACARDIAL: Arterial Stiffening</b> (reflected waves)</p>

2. *Cross-bridge detachments.* Impaired relaxation and increased ventricular stiffness may result from slow or incomplete cross-bridge detachment.

Abnormal cross-bridge detachment may result from reduced cAMP or cGMP-mediated phosphorylation of troponin-I, which increases calcium sensitivity of the myofibrils to calcium. Relaxation may also be impaired by alterations in the thick myofilaments as observed in genetic animal models [44], but whether this contributes to the development of relaxation disturbances in human heart failure is, however, still unknown.

Cross-bridge detachment can also be disturbed by perturbations in loading (preload and afterload). Enhanced preload delays onset and rate of relaxation, an effect that may become particularly relevant during beta-adrenergic stimulation as the lusitropic effects of adrenergic stimulation in tachycardia may become blocked by this mechanism [45, 46]. Effects of loading on the timing and rate of relaxation are complex, and dependent on the timing of load [47, 48]. The importance of inappropriate loading has been reemphasized in studies demonstrating abnormal ventricular–arterial interaction due to a disproportionate cardiovascular stiffening in patient with HFPEF. Stiffening-induced imbalances of the ventricular–arterial load may exacerbate systemic afterload, i.e., arterial impedance and reflected waves, and hence affect onset and rate of LV relaxation [49].

3. *Cytoskeletal abnormalities.* Proteins within the sarcomere, other than the myofibrils that generate active force, contribute substantially to the stiffness of the cardiac muscle over the normal range of the sarcomere length (<2.2  $\mu\text{m}$ ). These molecules include titin, tubulin, and desmin, but most of the elastic force of the sarcomere is thought to reside in titin [50]. Interestingly, titin is subject of intense regulation, including isoform switching, calcium binding and phosphorylation, indicating that myocardial resting tension can be dynamically regulated.

The two titin isoforms (N2B and N2BA) differ substantially in length and stiffness, with the N2B isoform being small and stiff. The distribution of these isoforms differs among species, heart chambers and disease states, and seems to track the corresponding variations in diastolic muscle stiffness [51]. Recent observations indicate that phosphorylation of titin may reverse the increased stiffness of cardiomyocytes in heart failure [52].

*ECM.* Changes in the structures within the ECM can also affect diastolic function (Fig. 1.2). The myocardial ECM is composed of three important constituents: (1) fibrillar protein, such as collagen type I, type III and elastin; (2) proteoglycans; and (3) basement membrane protein such as collagen type IV, laminin and fibronectin. It has been hypothesized that the most important component within the ECM that contributes to the development of diastolic dysfunction is fibrillar collagen (amount, geometry, distribution (especially as perimysial fibers), degree of cross-linking, ratio of collagen type I to III) [52–54]. Collagen synthesis is altered by load, both preload and afterload, by neurohormonal activation (e.g., the renin-angiotensin-aldosterone system- or RAAS—and the sympathetic nervous systems), and by growth factors. Collagen degradation is under the control of proteolytic enzymes including